Alkermes plc
Alkermes plc is a biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Alkermes' stock with a target price of $35.09, indicating strong growth potential.
Financial Health
Alkermes is performing well with strong revenue and cash flow, showing healthy profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ALKS
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical and regulatory milestones can move the share price; watch study readouts and approvals, though outcomes are uncertain.
R&D Intensity
High R&D spending supports innovation but increases cash-burn risk; funding and trial success are important to monitor.
Commercial & Partnerships
Revenue is a mix of product sales, royalties and collaborations; commercial uptake and payer decisions influence growth, and competition remains.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
